Lyell Immunopharma (LYEL) Leases (2020 - 2026)

Lyell Immunopharma's Leases history runs 7 years deep, the most recent figure standing at $17.8 million for Q1 2026.

• In Q1 2026, Leases fell 24.36% year-over-year to $17.8 million; the TTM figure through Mar 2026 stood at $17.8 million (down 24.36% YoY), while the FY2025 annual figure was $18.9 million, down 23.72% from the prior year.
• Leases came in at $17.8 million for Q1 2026 at Lyell Immunopharma, down from $18.9 million in the prior quarter.
• In the past five years, Leases ranged from a high of $45.7 million in Q1 2022 to a low of $17.8 million in Q1 2026.
• A 5-year average of $34.2 million and a median of $38.7 million in 2024 frame the typical range for Leases.
• Across the five-year window, Leases slipped 6.67% in 2022 and tumbled 45.69% in 2025, its largest moves.
• Lyell Immunopharma's Leases stood at $43.2 million in 2022, then dropped by 8.28% to $39.7 million in 2023, then sank by 37.63% to $24.7 million in 2024, then slipped by 23.72% to $18.9 million in 2025, then decreased by 5.53% to $17.8 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $17.8 million, $18.9 million, and $19.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison